Search articles in COVID-19
Filter Articles
Sections
- All (3,093 articles)
- Pharma Events (45 articles)
- For Recruiters (234 articles)
- Careers Events (5 articles)
- Partners (3 articles)
-
News
(2,572 articles)
- Industry Features (106 articles)
- Pharma Appointments (1,276 articles)
- COVID-19 (106 articles)
- Pharmaceuticals (654 articles)
- Biotechnology (139 articles)
- Clinical Research (223 articles)
- Artificial Intelligence (49 articles)
- Medical Devices (15 articles)
- Healthcare (21 articles)
- R & D (31 articles)
- Regulatory Affairs (44 articles)
- HR / Recruitment (5 articles)
- Sales / Commercial (10 articles)
- Manufacturing (4 articles)
- Medical Communications (2 articles)
- Careers Advice (262 articles)
- Company Focus (118 articles)
- Company Career Hubs (1 article)
- Pharma Training (6 articles)
- 25 Years of PharmiWeb (13 articles)
- DE&I (1 article)
Found 106 articles
Moderna Announces Memorandum of Understanding to Supply up to 110 Million Doses of Its COVID-19 Vaccine to the African Union
- 26 Oct 2021
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new Memorandum of Understanding (MoU) to make up to 110 million doses of the Moderna COVID-19 vaccine available to the African Union. The Company is prepared to deliver the first 15 million doses in the fourth quarter of 2021, 35 million doses in the first quarter of 2022, and up to 60 million doses in second quarter 2022.
NHS delivers booster vaccine to half of eligible people aged 50 and over
- 26 Oct 2021
Half of eligible people aged 50 and over have already received their COVID booster jab in England, as the biggest and fastest vaccination programme in NHS history continues.
NHS begins COVID-19 booster vaccination campaign
- 17 Sep 2021
The NHS has started delivering COVID booster jabs to people in eligible groups from today, as the biggest and most successful vaccination programme in health service history moves to the next stage.
Novavax to Participate in University of Oxford Com-COV3 Study Comparing Mixed COVID-19 Vaccine Schedule in Adolescents
- 17 Sep 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its participation in a newly expanded Phase 2 clinical trial called Comparing COVID-19 Vaccine Schedule Combinations – Stage 3 (Com-COV3), led by the University of Oxford and funded by the UK Vaccines Taskforce (VTF) and the National Institute for Health Research (NIHR).
Moderna Announces Health Canada Approves its COVID-19 Vaccine
- 17 Sep 2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced Health Canada has approved the New Drug Submission (NDS-CV) for SPIKEVAX™ (elasomeran mRNA vaccine), which has been known as COVID-19 Vaccine Moderna, for active immunization to prevent COVID-19 in individuals 12 years of age and older.
-
How Covid-19 is changing Job Seekers' Behaviours
- 24 Jul 2020
Unemployment rates across the globe have dramatically risen, yet despite that, so many countries have chosen to ignore COVID and do their best to recover economically.
Safety reporting continuity to protect patient safety and maintain compliance
- 7 May 2020
Scientists are working diligently to learn more about the Coronavirus and health boards are changing guidance to adapt to this newly available information. The response to this information varies on a regional and country level as does regulatory and submission guidance
Anti-viral surfaces could tackle COVID-19 crisis
- 6 May 2020
Some of the world’s leading coatings specialists gathered virtually at the Royal Society of Chemistry to discuss how special surface technologies could be used to tackle the global COVID-19 pandemic.
Roche’s COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark
- 6 May 2020
Roche today announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA)1 for its new Elecsys® Anti-SARS-CoV-2 antibody test. The test is designed to help determine if a patient has been exposed to the SARS-CoV-2 virus and if the patient has developed antibodies against SARS-CoV-2...
Pivotal to provide specialised clinical research services for new clinical trial with patients that have COVID-19
- 5 May 2020
Pivotal, has announced today that it has been contracted to provide specialised clinical research services in a clinical trial to study the efficacy and safety of hyperimmune plasma...
Medidata Accelerates Launch of myMedidata Platform, Responding to COVID-19
- 24 Apr 2020
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes.
BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates
- 22 Apr 2020
MAINZ, Germany and NEW YORK, April 22, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. (NYSE: PFE), have announced today that the German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 1/2 clinical trial for BioNTech’s BNT162 vaccine program to prevent COVID-19 infection.
Laboratory relocation firm offers free support for NHS
- 22 Apr 2020
Specialist laboratory relocation and storage provider, Aport, is offering free support to the NHS in the regions surrounding its UK headquarters.
Sanofi and Luminostics to join forces on developing breakthrough COVID-19 smartphone-based self-testing solution
- 16 Apr 2020
Sanofi and Luminostics have signed an agreement to evaluate a collaboration on a unique self-testing solution for COVID-19, using Luminostics’ innovative technology, and further adding to Sanofi’s ongoing efforts to fight the COVID-19 pandemic on multiple fronts.
NovaBiotics announces fast-track repurposing of its experimental drug Nylexa for COVID-19 trials and plans for earliest possible compassionate use
- 14 Apr 2020
NovaBiotics, the clinical stage antimicrobials drug discovery company, announces the rapid repurposing of Nylexa for the ‘hidden killer’ underlying COVID-19: secondary bacterial lung infections.
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
- 14 Apr 2020
Sanofi and GSK today announce that they have signed a letter of intent to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic.
FDA CLEARS INVESTIGATIONAL NEW DRUG APPLICATION FOR MESOBLAST TO USE REMESTEMCEL-L IN PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME CAUSED BY COVID-19
- 9 Apr 2020
Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory diseases, today announced that it has received clearance from the United States Food and Drug Administration (FDA)
Mallinckrodt and Novoteris Receive Clearance from Health Canada to Start Pilot Trial of High-Dose Inhaled Nitric Oxide Therapy for COVID-19 Infection and Associated Lung Complications
- 8 Apr 2020
Study to investigate antiviral activity and improvement in oxygenation and pulmonary arterial pressure in patients suffering from COVID-19
Celltrion Healthcare secure 300 COVID-19 antibody candidates in efforts to develop antiviral
- 8 Apr 2020
Celltrion Group today announced its successful transition to the second phase of development for an antiviral treatment to fight the novel coronavirus (COVID-19) pandemic, following the completion of the first phase of securing 300 different types of antibodies that bind to the antigen last month. The library of antibodies was created using the blood of recovered patients in Korea.
